With four late-stage assets, three FDA Breakthrough Therapy Designations, and two upcoming PDUFA decisions, Praxis Precision Medicines (PRAX), a CNS precision neuroscience biopharmaceutical company, is entering a defining chapter.

(RTTNews) - With four late-stage assets, three FDA Breakthrough Therapy Designations, and two upcoming PDUFA decisions, Praxis Precision Medicines (PRAX), a CNS precision neuroscience biopharmaceutical company, is entering a defining chapter. The two drug candidates under FDA review are <b>Ulixacaltamide</b> and <b>Relutrigine</b>.

A new study demonstrates that human overconfidence persists because its decision-making costs make it a credible, peacock-like evolutionary signal of underlying ability.

The University of Toronto is ranked fourth in the world - and second among public universities - in the latest NTU World University Rankings .U of T

Eli Lilly and Company, McKesson, Pfizer, Zoetis, Johnson & Johnson, Merck & Co., Inc., and Gilead Sciences are the seven Pharmaceutical stocks to watch today, according to MarketBeat’s stock screener tool. Pharmaceutical stocks are shares of publicly traded companies that research, develop, manufacture, and sell medicines, vaccines, and other drug-related products. For stock market investors, [...]

ProShares UltraPro Short QQQ, Novo Nordisk A/S, Chevron, International Business Machines, Pfizer, Bristol Myers Squibb, and NIKE are the seven Dividend stocks to watch today, according to MarketBeat’s stock screener tool. Dividend stocks are shares of companies that regularly distribute a portion of their profits to shareholders, typically in the form of cash payments called [...]

Researchers have developed a computer model of the human cortex that links its microscopic chemistry to its brain-wide patterns of activity, providing new evidence that regional differences in receptor density help shape how activity and information move across the brain.

Maplight Therapeutics, Inc. (NASDAQ:MPLT – Get Free Report) dropped 6.4% during trading on Friday . The company traded as low as $12.30 and last traded at $12.43. Approximately 102,568 shares traded hands during trading, a decline of 77% from the average session volume of 453,138 shares. The stock had previously closed at $13.28. Wall Street [...]

NEWARK - Seniors in public housing are slipping into dementia, often alone, with no financial resources and no family to spot the warning signs, according to a Rutgers screening. The Newark screening revealed severe cognitive decline among isolated, low-income seniors, prompting Rutgers researchers to launch an intervention program that connects them with clinical care at geriatric and neurology practices. When Payton White, a doctoral student at Rutgers University–Newark, began a memory screening program for African American seniors living in public housing in the local area, she expected to find a few cases of mild dementia. Instead, she encountered people who thought the year was 1988. Some thought it was 1923. Of the 160 people screened in the first half-year of the program, roughly two-thirds had memory decline more severe than usual for their age. Of those, nearly half showed memory loss consistent with mild, moderate or even severe dementia, according to White. “I thought, ‘This can't be,’” said White, who works with her doctoral adviser Mark Gluck, a professor of neuroscience who heads the Aging & Brain Health Alliance at Rutgers University-Newark. White found the common denominator among the seniors to be isolation, without financial resources or loved ones nearby to recognize signs of decline and offer support. “They are facing dementia alone,” said Gluck, a neuroscientist who for more than a decade has researched dementia and Alzheimer’s disease among African Americans who develop the illness at more than twice the rate of other groups. Gluck said the increase in low-income adults facing dementia alone is a rising public health crisis, one that reverberates beyond Newark and affects many public-housing residents, not just African Americans. “This is an all-hands-on-deck, brain-health emergency in Newark,” Gluck said. Gluck has led programs in the Greater Newark area for the past 20 years to spread awareness of Alzheimer’s disease and help reduce risks among African Americans, including community-based exercise classes. The plan by members of the Aging & Brain Health Alliance at Rutgers includes a collaboration among various schools and units at Rutgers, as well as regional health care providers. They identify seniors coping with dementia in isolation and connect them with clinical care at geriatric and neurology practices that provide dementia and memory assessment and treatment. “One of our primary goals is identifying people in the earliest stages of Alzheimer’s disease before significant progression occurs – when early diagnosis, treatment and intervention can have the greatest potential impact,” Gluck said. “This is not just a care-management effort. Early screening and rapid connection to clinical care are crucial to address the growing problem of dementia in lower-income adults, especially African Americans who suffer from Alzheimer’s disease and related dementias at very high rates.” Graduate students at the Rutgers School of Nursing, known as Community Brain Health Navigators, will be working with residents. They will help seniors make appointments, arrange a car service to the clinics, bring them home and then explain next steps. Gluck is also seeking navigators among graduate students at the Rutgers School of Public Health. But the first step is to identify the elders whose dementia is progressing and going unnoticed by neighbors and loved ones. “If you're not with that person every day, you might not notice,” said White. Far-off family members may be lulled into thinking their loved one is just fine, especially if they have friends in the building and participate in planned activities. “A lot of times, families see them doing the normal stuff, so, they think, ‘Oh, it's not that bad,'” said Tuesday M. Whitney, the family self-sufficiency program manager at the East Orange Housing Authority, a partner of the Aging & Brain Health Alliance. Gluck is seeking funding to expand the Brain Health Navigation effort in the Newark area and other parts of New Jersey. His brain health education and care navigation initiatives are funded by a $100,000 grant from The Hearst Foundations and an ongoing grant of $587,000 from Eli Lilly and Co. But with the current funding and staffing, Gluck said Brain Health Navigators are only making a dent in solving this regional and national problem. Many seniors found to be cognitively impaired are initially referred to University Hospital's Center for Memory and Brain Health, a new memory-loss and dementia clinic run by Jack Tsao, a professor of neurology at the Herbert and Jacqueline Krieger Klein Alzheimer’s Research Center at Rutgers Brain Health Institute. Additional care is provided by Padam Neopane and colleagues in the Rutgers New Jersey Medical School Department of Family Medicine and the Division of Geriatrics. Students from the Rutgers School of Nursing will be trained in the best ways to communicate with someone with moderate dementia. Angela Starkweather, dean and chief academic officer of the Rutgers School of Nursing, said students will also learn how to work with family members who might be unaware of the decline in their parents' cognitive health. “These are some hard conversations to have, so you want to give them the language they need to reach people in the right way,” she said. Starkweather offered a simple explanation for why the School of Nursing agreed so readily to help get these community members into care as quickly as possible: “It’s needed now.”

NEW YORK, Aug. 07, 2026 (GLOBE NEWSWIRE) -- The PSP Trial Platform (PTP), a landmark clinical trial testing multiple drugs simultaneously in the search for effective PSP treatments, has enrolled its first participant. Progressive supranuclear palsy (PSP) is a rare brain disorder that can mimic Parkinson’s disease in loss of balance, movement disorders and stiffness. There is no cure and no approved treatment, in part due to the limited number of clinical trials for potential treatments. Led by the University of California, San Francisco (UCSF) and funded by a five-year grant of up to $75.4 million from the National Institute on Aging (NIA), the PTP is being conducted at 50 sites nationwide. Modeled on the HEALY ALS Platform Trial, it tests multiple drugs concurrently - and new ones can be added as they become available - accelerating discovery without starting from scratch each time. The trial aims to enroll 440 participants over 2 years. Unlike traditional clinical trials, the PTP is designed so that 75% of participants receive an active drug during the first year, reducing the number of patients assigned to placebo. After that, all participants receive an active drug. "We expect this trial to rapidly accelerate efforts to identify effective PSP therapies by increasing the number of promising drugs tested, while expanding access to potential treatments to more patients. It will also create a wealth of longitudinal data to enable researchers to better understand the causes of PSP and develop new diagnostic tests and therapies,” said Adam Boxer, MD, PhD, Endowed Professor in Memory and Aging at UCSF, and lead study Principal Investigator. "The enrollment of the first participant marks the beginning of an important new chapter for the PSP community,” said Kristophe Diaz, PhD, Chief Executive Officer of CurePSP. "The PTP is one of the most ambitious collaborative efforts ever undertaken in PSP research, bringing together leading researchers, trial sites, industry, government and nonprofit organizations to accelerate the development of better therapies.” "This is good news for patients and their families who are struggling with this disease. We are hopeful that this enrollment is the first step towards finding an effective treatment for this illness,” said Anne-Marie Wills, MD, MPH, Director of the CurePSP Center of Care at Massachusetts General Hospital, and study co-Principal Investigator. Two of the drugs being tested are LM11A-31, from PharmatrophiX, and AADvac1, from Axon Neuroscience. "Rather than targeting a single downstream consequence of disease, LM11A-31 is designed to protect neurons and their synaptic connections while addressing multiple mechanisms that drive neurodegeneration, including toxic tau biology,” said Dr. Frank M. Longo, Co-Founder of PharmatrophiX. "The first patient enrolled represents more than the start of a clinical trial, it is the beginning of a potential paradigm shift for these patients and families.” "AADvac1's inclusion is an important step forward, built on more than two decades of our dedicated research into tau protein, a key driver of the disease pathology in PSP,” said Michal Fresser, CEO of Axon Neuroscience. "We remain committed to advancing science that may one day lead to meaningful therapy options.” The PTP is open to patients with Richardson's syndrome who have experienced progressive symptoms for fewer than five years and are accompanied by a care partner. For more information, visit our website at https://www.psp.org/ptp or view our ClinicalTrials.gov listing (NCT07173803) https://clinicaltrials.gov/study/NCT07173803 for a complete list of eligibility criteria. You can also complete the UCSF PSP Trials Prescreening survey to see if you may be eligible for any currently enrolling PSP trials, including PTP. About UCSF The University of California, San Francisco (UCSF) is exclusively focused on the health sciences and is dedicated to promoting health worldwide through advanced biomedical research, graduate-level education in the life sciences and health professions, and excellence in patient care. UCSF Health, which serves as UCSF’s primary academic medical center, includes top-ranked specialty hospitals and other clinical programs, and has affiliations throughout the Bay Area. UCSF School of Medicine also has a regional campus in Fresno. Learn more at https://ucsf.edu or see our Fact Sheet. About CurePSP CurePSP is the leading nonprofit organization dedicated to the awareness, care and cure for three neurodegenerative diseases: progressive supranuclear palsy (PSP), corticobasal degeneration (CBD) and multiple system atrophy (MSA). As a catalyst for new treatments and a cure, CurePSP establishes important partnerships and funds critical research internationally. Through its advocacy and support efforts, CurePSP enhances education, care delivery and quality of life for people living with PSP, CBD and MSA and their families. Science, community and hope are at the heart of CurePSP's mission and all its services. CurePSP is a registered 501(c)(3) charity within the United States (EIN: 52-1704978). Contact: Kristophe Diaz, PhD Chief Executive Officer, CurePSP 646-725-1453 diaz@curepsp.org